European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes

G Valentini, A Della Rossa, S Bombardieri, W Bencivelli, A J Silman, S D'Angelo, M M Cerinic, J F Belch, C M Black, P Bruhlmann, L Czirják, A De Luca, A A Drosos, C Ferri, A Gabrielli, R Giacomelli, G Hayem, M Inanc, N J McHugh, H Nielsen, M Rosada, R Scorza, J Stork, A Sysa, F H van den Hoogen, P J Vlachoyiannopoulos, G Valentini, A Della Rossa, S Bombardieri, W Bencivelli, A J Silman, S D'Angelo, M M Cerinic, J F Belch, C M Black, P Bruhlmann, L Czirják, A De Luca, A A Drosos, C Ferri, A Gabrielli, R Giacomelli, G Hayem, M Inanc, N J McHugh, H Nielsen, M Rosada, R Scorza, J Stork, A Sysa, F H van den Hoogen, P J Vlachoyiannopoulos

Abstract

Objective: To develop criteria for disease activity in systemic sclerosis (SSc) that are valid, reliable, and easy to use.

Methods: Investigators from 19 European centres completed a standardised clinical chart for a consecutive number of patients with SSc. Three protocol management members blindly evaluated each chart and assigned a disease activity score on a semiquantitative scale of 0-10. Two of them, in addition, gave a blinded, qualitative evaluation of disease activity ("inactive to moderately active" or "active to very active" disease). Both these evaluations were found to be reliable. A final disease activity score and qualitative evaluation of disease activity were arrived at by consensus for each patient; the former represented the gold standard for subsequent analyses. The correlations between individual items in the chart and this gold standard were then analysed.

Results: A total of 290 patients with SSc (117 with diffuse SSc (dSSc) and 173 with limited SSc (lSSc)) were enrolled in the study. The items (including Delta-factors-that is, worsening according to the patient report) that were found to correlate with the gold standard on multiple regression were used to construct three separate 10-point indices of disease activity: (a) Delta-cardiopulmonary (4.0), Delta-skin (3.0), Delta-vascular (2.0), and Delta-articular/muscular (1.0) for patients with dSSc; (b) Delta-skin (2.5), erythrocyte sedimentation rate (ESR) >30 mm/1st h (2.5), Delta-cardiopulmonary (1.5), Delta-vascular (1.0), arthritis (1.0), hypocomplementaemia (1.0), and scleredema (0.5) for lSSc; (c) Delta-cardiopulmonary (2.0), Delta-skin (2.0), ESR >30 mm/1st h (1.5), total skin score >20 (1.0), hypocomplementaemia (1.0), scleredema (0.5), digital necrosis (0.5), Delta-vascular (0.5), arthritis (0.5), TLCO <80% (0.5) for all patients with SSc. The three indexes were validated by the jackknife technique. Finally, receiver operating characteristic curves were constructed in order to define the value of the index with the best discriminant capacity for "active to very active" patients.

Conclusions: Three feasible, reliable, and valid preliminary indices to define disease activity in SSc were constructed.

Figures

Figure 1
Figure 1
Receiver operating characteristic curves showing the relation between the value of the calculated activity index and the presence of active or very active disease in (A) SSc whole series; (B) dSSc; (C) lSSc. AUC = area under the curve.

References

    1. Clin Exp Immunol. 1978 Mar;31(3):351-6
    1. J Rheumatol. 1999 Oct;26(10):2159-67
    1. Arthritis Rheum. 1980 May;23(5):581-90
    1. Arthritis Rheum. 1982 Oct;25(10):1167-73
    1. Clin Exp Rheumatol. 1986 Oct-Dec;4(4):367-9
    1. J Rheumatol. 1986 Oct;13(5):911-6
    1. Ann Rheum Dis. 1987 Oct;46(10):763-7
    1. J Rheumatol. 1988 Feb;15(2):202-5
    1. Arthritis Rheum. 1988 Jul;31(7):817-25
    1. Br J Rheumatol. 1989 Apr;28(2):98-103
    1. Arthritis Rheum. 1990 Mar;33(3):375-80
    1. Br J Dermatol. 1991 May;124(5):423-8
    1. BMJ. 1992 Jun 6;304(6840):1491-4
    1. Clin Exp Rheumatol. 1992 Sep-Oct;10(5):521-5
    1. Clin Exp Rheumatol. 1992 Sep-Oct;10(5):541-7
    1. J Rheumatol. 1993 Mar;20(3):552-4
    1. Ann Rheum Dis. 1993 Apr;52(4):272-7
    1. Arthritis Rheum. 1993 Jun;36(6):729-40
    1. Immunol Res. 1993;12(3):312-6
    1. Arthritis Rheum. 1994 Apr;37(4):454-62
    1. Arthritis Rheum. 1995 Feb;38(2):184-9
    1. J Rheumatol. 1995 Apr;22(4):654-8
    1. Baillieres Clin Rheumatol. 1995 May;9(2):253-66
    1. Baillieres Clin Rheumatol. 1995 May;9(2):267-85
    1. Br J Rheumatol. 1996 Apr;35(4):364-72
    1. Rheum Dis Clin North Am. 1996 Nov;22(4):675-94
    1. Adv Exp Med Biol. 1997;428:1-5

Source: PubMed

3
Iratkozz fel